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ABSTRACT

The present invention provides, inter alia, a novel process
for the preparation of Citalopram, a known antidepressant.
12 Claims, 5 Drawing Sheets
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excessive handling of a flammable liquid, i.e., diethyl ether.
The work-up involves the following steps:
The reaction mixture is quenched into ice water;
CROSS-REFERENCE TO RELATED
An aqueous saturated ammonium chloride solution IS
APPLICATION
5
added;
The present application claims priority to U.S. Provisional
The mixture is extracted with diethyl ether;
Patent Application No. 60/324,821, filed Sep. 24, 2001, the
The ether phase is then extracted with 20% aqueous acetic
teachings of which are incorporated herein by reference for
acid;
all purposes.
The
acid phase is made alkaline with 10 N aqueous
10
sodium hydroxide;
BACKGROUND OF THE INVENTION
The aqueous phase is extracted with diethyl ether (2x);
Citalopram is an antidepressant drug that is widely used
The combined ethereal extracts are dried over anhydrous
in both the United States and Europe. Its mode of action and
~C03;
activity have been described in various publications. The 15
The ether extract is treated with activated carbon; and
active ingredient is an HBr or oxalate salt, preferably an HBr
The solvent is evaporated in vacuum to give Br-Diol, an
salt. Citalopram has the following structure:
oil.
The above work-up process is very laborious and is not
NC
suited for large-scale production. Again, it involves the
20 excessive handling of flammable solvents, such as diethyl
CH3
ether, and it involves numerous unit operations, thereby
/
(CHzhN
·HBr
reducing productivity. Moreover, it is noted that Br-Diol is
\
isolated as the free amine and is an oil. The physical
CH3
characteristics of Br-Diol are important. Since Br-Diol is an
25 oil, it cannot be isolated as a crystalline solid and, thus, it
cannot be purified by techniques such as crystallization/
recrystallization. Purification of this oil by crystallization or
F
similar techniques is not described. It is believed that this is
one of the major reasons why the process described in U.S.
30
Pat. No. 4,136,193 fails to provide Citalopram in the quality,
Several processes have been described in the literature for
i.e., purity, required for drug applications. In addition, in
preparing Citalopram (see, Drugs of Future, 25(6):620
order to meet the tight specifications for Citalopram, it is
(2000). Citalopram was first disclosed in German Patent
critical that purity is established at this stage.
2,657,271, which is the German equivalent of now expired
In step three, Br-Diol is subjected to a ring closure
U.S. Pat. No. 4,136,193. In this patent, 5-bromophthalide
35
reaction with 60% aqueous phosphoric acid. In a typical
(5-BP) was converted via a five-step reaction sequence to
reaction, 5-bromophthalide is heated with excess (30
Citalopram. This route for preparing Citalopram is depicted
equivalents) 60% aqueous phosphoric acid for 3 h and then
in FIG. 1, and constitutes the basis of several patents and
neutralized with saturated aqueous ammonia. The resulting
patent applications.
mixture is then extracted with diethyl ether, and the ether
Attempts to reproduce the process described in U.S. Pat.
No. 4,136,193 for the preparation of Citalopram in the 40 extract is dried over potassium carbonate. The ether extract
is then treated with activated charcoal and stripped of
quality specifications required for its use in pharmaceutical
solvent under reduced pressure to give the compound of
applications have been unsuccessful. It is noted that the
Formula IV ("5-Br").
quality specifications for pharmaceutical quality Citalopram
As mentioned above, step three employs a large excess of
are extremely stringent and require material with purity in
45 60% aqueous phosphoric acid. This is troublesome because
excess of 99.7%. Difficulty encountered in manufacturing
on reaction completion excess phosphoric acid has to be
Citalopram of the required purity by the process described in
neutralized with ammonia. Neutralization is an extremely
German Patent No. 2,657,013, U.S. Pat. No. 4,136,193 and
exothermic process and heat management becomes a major
PCT International Publication Nos. WO 00/11926 and WO
00/13648 was recently described by Lundbeck in WO 50 issue in the commercial-scale production of this material. In
addition, the use of such a large excess of phosphoric acid
01/45483 A2 (see, page 2, line 26).
increases the cost of commercial scale operations due to the
Following is the detailed description of the process
use of excess reagents, longer cycle times and reduced
described in U.S. Pat. No. 4,136,193. It is noted that the
loading. Moreover, from a safety point of view, the use of
experimental process described in U.S. Pat. No. 4,136,193 is
flammable solvents, such as diethyl ether, is discouraged for
for the 4-chlorophenyl analog, but it is noted therein that the 55
the commercial-scale production of organic compounds.
process is applicable to the 4-fluorophenyl derivative as
In step four, 5-Br is reacted with cuprous cyanide in DMF
well. As illustrated in FIG. 1, the process described in U.S.
to give, after the work-up, Citalopram. The reaction condiPat. No. 4,136,193 involves a 5-step conversion of
tions and work-up for the process described in U.S. Pat. No.
5-bromophthalide to Citalopram.
4,136,193 is as follows:
In the first step, a compound of Formula I ("5-BP") is 60
5-Br is reacted with CuCN in DMF at reflux for 4 h;
reacted with p-fluorophenyl-magnesium halide; in the secThe reaction mixture is cooled to 55° C. and quenched
ond step, the intermediate of a compound of Formula II is
into an aqueous solution of ethylene diamine;
isolated
and
reacted
with
N,NThe oily layer is separated and the aqueous layer is
dimethylaminopropylmagnesium halide to give the diol of
extracted with benzene;
Formula III ("Br-Diol"). The Grignard reaction is conducted 65
The combined organic phases are washed with 10%
in traditional solvents, such as diethyl ether and THE
aqueous sodium cyanide;
Unfortunately, the work-up is very complex and involves
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The organic layer is dried, treated with activated carbon,
DETAILED DESCRIPTION OF THE
and concentrated under vacuum to give an oil;
INVENTION AND PREFERRED
The oil is dissolved in ether and extracted with aqueous
EMBODIMENTS
acetic acid;
The acetic acid layer is made alkaline with 10 N aqueous 5
The present invention provides a process for the prepasodium hydroxide and extracted with ether; and
ration of Citalopram and, in particular, Citalopram.HBr.
The ethereal extract is dried over K 2 C0 3 , treated with
FIG. 2 illustrates an exemplary process for the preparation
activated charcoal, and stripped of solvent to give
of Citalopram.HBr in accordance with the present invention.
Citalopram.
Unfortunately, there are numerous problems with step 10
four. First, the reaction does not go to completion in 4 h; in
As illustrated in FIG. 1, the present invention provides a
reality, conversion after 4 h is <10%. Removal of unreacted
salt of the compound of Formula III, which can be isolated
5-Br is difficult and normal purification techniques, such as
as a crystalline material, and a novel, simplified process for
extraction, crystallization, etc., are not effective. When the
reaction is pushed to achieve higher conversion, formation 15 preparing such salt. The ability to isolate a salt of the
compound of Formula III allows one to set the purity at this
of numerous unidentified side-products is observed. In short,
step by allowing one to get rid of impurities that would
the process described in U.S. Pat. No. 4,136,193 does not
otherwise be carried through the process, making it imposwork to provide acceptable quality Citalopram. Moreover,
sible to prepare high quality Citalopram.
the work-up is laborious and involves the use of undesirable
20
solvents such as benzene and diethyl ether.
In the fifth and final step of the process described in U.S.
As such, in one embodiment, the present invention proPat. No. 4,136,193, Citalopram is converted to Citalopramvides a crystalline salt of the compound of Formula III
.HBr or the oxalate salt in the conventional manner-a
having the following structure:
process is not described for this conversion.
Another route for the preparation of Citalopram has been 25
III
described in U.S. Pat. No. 4,650,884. This process is based
OH
on 5-cyanophthalide (,,5-CN"). In this process, 5-CN is
Br
reacted with 4-fiuorophenylmagnesium halide and N,Ndimethylaminopropylmagnesium halide to give the corresponding hydroxy intermediate that is then dehydrated with 30
sulfuric acid to give Citalopram.
Although a number of processes have been described for
the preparation of Citalopram, there remains a need in the art
for additional processes that can be prepared in high yield,
at the quality specifications required for use in pharmaceu_ 35
tical applications and without the limitations of the prior art
method disclosed in now expired U.S. Pat. No. 4,136,193.
F
Quite surprisingly, the present invention fulfills these and
other needs.
40

SUMMARY OF THE INVENTION
The present invention provides a novel process for the
preparation of Citaopram and, in particular, Citalopram.HBr.
Using the process of the present invention, Citalopram.HBr
can be readily prepared in high yields, at the quality specifications required for use in pharmaceutical applications
(i.e., greater than 99.7% pure) and without the limitations of
the prior art methods.
Other features, objects and advantages of the invention
and its preferred embodiments will become apparent from
the detailed description which follows.

45

In a presently preferred embodiment, the crystalline salt is
an acid salt. Suitable acid salts include, but are not limited
to, a HCI salt, a HBr salt, a H 2 S0 4 salt, a H 3 P0 4 salt, a
methanesulfonic acid salt, a trifiuoroacetic acid salt, an
acetic acid salt, a fumaric acid salt and a citric acid salt. In
a presently preferred embodiment, the crystalline salt is an
HCI salt having the following structure:
OH

50
Br

BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 illustrates a prior art process used to prepare
Citalopram. This process was originally disclosed in now
expired U.S. Pat. No. 4,136,193.
FIG. 2 illustrates a process in accordance with one aspect
of the present invention that can be used to prepare Citalopram in high yield and at the quality specifications required
for use in pharmaceutical applications.
FIG. 3 illustrates an example of a feed composition to be
purified.
FIG. 4 illustrates that the product contained in the extract,
i.e., the recovered extract, does not contain any detectable
amounts of 5-Br.
FIG. 5 illustrates the recovered raffinate.

55

60
F

65

In another aspect, the present invention provides a method
for preparing the salt of the compound of Formula III, the
process comprising: (a) contacting a compound of Formula
I having the following structure:

US 6,967,259 B2
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not limited to, diethylether, t-butylmethylether, THF,
dioxane, toluene, xylene and mixtures thereof. In a preferred
embodiment, the organic solvent used in step (b) is a mixture
of THF and toluene.
0;
In a preferred embodiment, the above method further
5
#
comprises: (d) isolating the salt of the compound of Formula
III from the product mixture. In one embodiment, step (d)
o
comprises: (i) filtering the product mixture to obtain the salt
of the compound of Formula III. In another embodiment,
with 4-fiuorophenyl magnesium bromide to form an interstep (d) further comprises: (ii) washing the salt of the
mediate of Formula II having the following structure:
10
compound of Formula III with water and toluene. In yet
another embodiment, step (d) further comprises: (iii) recrysII
tallizing the salt of the compound of Formula III from a
member selected from the group consisting of I-butanol,
15 2-butanol and water. In a preferred embodiment, the salt of
the compound of Formula III is recrystallized from
2-butanoI.
In another aspect, the present invention provides a method
for preparing a compound of Formula IV having the fol20 lowing structure:

Br'Cq
I

Br

Br

IV

F

25

(b) contacting the intermediate of Formula II with dimethylaminopropyl magnesium chloride in an organic solvent to
form a reaction mixture; and (c) quenching the reaction
mixture with an acid to form a product mixture comprising
the salt of the compound of Formula III. In one embodiment
of the above process, the crystalline salt is an acid salt.
Suitable acid salts include, but are not limited to, a HCl salt,
a HEr salt, a H 2 S0 4 salt, a H 3 P0 4 salt, a methanesulfonic
acid salt, a trifiuoroacetic acid salt, an acetic acid salt, a
fumaric acid salt and a citric acid salt. In a presently
preferred embodiment, the crystalline salt is an HCl salt
having the following structure:

30
F

35

III

OH

Br

the method comprising: (a) contacting a salt of the compound of Formula III having the following structure:

40

OH

Br

45

F
F

In connection with this particular embodiment, it has been
surprisingly found that depending on the isolation and
recrystallization procedures used to isolate the HCl salt of
the compound of Formula III, different polymorphs are
obtained. For instance, the crude HCl salt of the compound
of Formula III, isolated from a mixture of THF/toluenel
aqueous HCl has one melting point, whereas the crude HCl
salt of the compound of Formula III recrystallized from
butanol has a second melting point.
As such, in one embodiment, the acid used in step (c) is
a member selected from the group consisting of HCl, HEr,
H 2 S0 4 , H 3 P0 4 , methanesulfonic acid, trifiuoroacetic acid,
acetic acid, fumaric acid and citric acid. Again, in a preferred
embodiment, the acid is aqueous HCI.
In one embodiment, the solvent used in step (b) is an
organic solvent. Suitable organic solvents include, but are

50

55

60

65

with about 2 to about 10 equivalents of phosphoric acid to
form a reaction mixture; (b) adding an organic solvent to
said reaction mixture; and (c) quenching said reaction mixture with base to form a product mixture comprising said
compound of Formula IV.
With respect to this method, the patent literature (e.g.,
U.S. Pat. No. 4,136,193) teaches that an excess of 60%
phosphoric acid (-30 equivalents) is required in order to
achieve ring closure. However, it has now been surprisingly
found that ring closure can be achieved with significantly
fewer equivalents of phosphoric acid (e.g., about 2 to about
10 equivalents). This finding gives rise to a purer product
and numerous other advantages. For instance, one of the
problems associated with the process disclosed in U.S. Pat.
No. 4,136,193 for making Citalopram is neutralization of
excess phosphoric acid with ammonia. As expected, this
reaction is very exothermic and takes a long time to neu-

US 6,967,259 B2
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tralize the reaction mixture. Long neutralization time
equates to longer cycle time, which in turn means lower
productivity. Since fewer equivalents of phosphoric acid are
used and the amount of ammonia needed to quench the
excess phosphoric acid is reduced, the overall batch size is 5
higher than the normal batch size by nearly 20%. As such,
the method of the present invention provides purer product,
is more suited for commercial scale production, and has
much higher productivity.
10

IV
Br

In one embodiment, the salt of the compound of Formula
F
III is a HCI salt. In another embodiment, the phosphoric acid
is about 20% to about 60% phosphoric acid. In a preferred
with a mixture of cuprous cyanide and sodium cyanide to
embodiment, the compound of Formula III is contacted with 15 form a reaction mixture; (b) heating the reaction mixture
until the reaction is complete; and (c) quenching the reaction
about 6 to about 9 equivalents of 20% phosphoric acid. In
mixture to form a product mixture comprising the compound
another preferred embodiment, the compound of Formula III
of Formula V. It has been found that a mixture of cyanating
is contacted with about 9 equivalents of 20% phosphoric
agents works surprisingly well for carrying out this method.
acid. It will be readily apparent to those of skill in the art that
20
In one embodiment, the compound of Formula IV is in a
other acids can be used in place of phosphoric acid. Suitable
first organic solvent. Suitable first organic solvents include,
acids include, but are not limited to, HCI, HEr, sulfuric acid,
but are not limited to, toluene, benzene, xylene, diethylether,
trifiuoroacetic acid,and methane sulfonic acid, etc.
t-butylmethylether, dioxane, and mixtures thereof. In a preferred embodiment, the first organic solvent is toluene. In
In another embodiment, the organic solvent in step (b) is
25 another embodiment, the mixture of cuprous cyanide and
a member selected from the group consisting of toluene,
sodium cyanide is in a second organic solvent. Suitable
benzene, xylene, diethylether, t-butylmethylether, dioxane,
second organic solvents include, but are not limited to,
and mixtures thereof. In a preferred embodiment, the
N,N -dimethylformamide, N,N -dimethylacetamide,
organic solvent in step (b) is toluene.
N-methylpyrrolidione, quinoline, collidine, xylene,
30 dimethylsulfone, hexamethylphosphoramide and trifiuoIn another embodiment, the base is a member selected
romethylchlorobenzene. In a preferred embodiment, the
from the group consisting of ammonium hydroxide, sodium
second organic solvent is N,N-dimethylformamide.
hydroxide and potassium hydroxide. In a presently preferred
It will be readily apparent to those of skill in the art that
embodiment, the base is aqueous ammonium hydroxide.
the ratio of cuprous cyanide:sodium cyanide in the mixture
35 of cuprous cyanide and sodium cyanide can be varied. In a
In a preferred embodiment, the above method further
presently preferred embodiment, the ratio of cuprous cyacomprises: (c) isolating the compound of Formula IV from
nide:sodium cyanide in the mixture of cuprous cyanide and
the product mixture. In one embodiment, step (c) comprises:
sodium cyanide is about 2.5:1.0 to about 1:2.5. In a presently
(i) separating the organic phase and the aqueous phase; (ii)
preferred embodiment, the ratio of cuprous cyanide:sodium
re-extracting the aqueous phase with toluene; (iii) combin- 40 cyanide in the mixture of cuprous cyanide and sodium
ing the organic phases to form a combined organic phase and
cyanide is about 0.50:1.0 to about 2.5:1. In another preferred
washing the combined organic phase with water; and (iv)
embodiment, the ratio of cuprous cyanide:sodium cyanide in
distilling the washed organic phase to obtain the compound
the mixture of cuprous cyanide and sodium cyanide is about
0.75: 1.0 to about 1.0: 1.0. It will be readily apparent to those
of Formula IV.
45 of skill in the art that other mixtures of cyanating agents
In a preferred embodiment, the above method is carried
(e.g., KCN:CuCN or Metal-CN:CuCN complexes) can be
out at a temperature of about 80° C.±10° C.
used in the above method of the present invention.
In one embodiment, the first organic solvent is removed
In another aspect, the present invention provides a method
from the reaction mixture prior to step (b). In another
for preparing a compound of Formula V having the follow- 50 embodiment, the reaction mixture is quenched with a meming structure:
ber selected from the group consisting of aqueous sodium
cyanide and aqueous potassium cyanide. In a preferred
v
embodiment, the reaction mixture is quenched with 10%
NC
aqueous sodium cyanide.
55
In a preferred embodiment, the above method further
comprises: (d) isolating the compound of Formula V from
the product mixture. In one embodiment, step (d) comprises:
(i) adding ethylenediamine and a first organic solvent to the
reaction mixture and separating the organic phase and the
60 aqueous phase; (ii) re-extracting the aqueous phase with the
first organic solvent; (iii) combining the organic phases to
form a combined organic phase and back-extracting the
F
combined organic phase with an acid to form an acid extract;
(iv) neutralizing the acid extract with a base to a pH of about
65 8.5 to about 11 to form a neutralized extract; (v) extracting
the method comprising: (a) contacting a compound of Forthe neutralized extract with a second organic solvent to form
mula IV having the following structure:
a second organic solvent extract; (vi) treating the second

US 6,967,259 B2
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organic solvent extract with charcoal and removing the
second organic solvent to generate the compound of Formula V.
In a preferred embodiment of step (d), the first and second
organic solvents are independently selected from the group
consisting of toluene, benzene, xylene, diethylether,
t-butylmethylether, dioxane, and mixtures thereof. In
another preferred embodiment, the first and second organic
solvents are both toluene.
In one embodiment, the acid in step (iii) is a member
selected from the group consisting of HCl, HBr, H 2 S0 4 ,
H 3 PO 4' trifiuoroacetic acid and acetic acid. In a preferred
embodiment, the acid in step (iii) is 20% aqueous acetic
acid. In one embodiment, the base in step (iv) is a member
selected from the group consisting of sodium hydroxide,
potassium hydroxide and sodium carbonate. In a preferred
embodiment, the base in step (iv) is sodium hydroxide. In
one embodiment, the acid extract in step (iv) is neutralized
with the base to a pH of about 9 to about 10.
In another aspect, the above method further comprises
purifying the compound of Formula V using simulated
moving bed (SMB) chromatography having a stationary
phase and a mobile phase. It has been found that 5MB
chromatography works surprisingly well for removing nonpolar impurities found in the reaction mixture. In one
embodiment, the stationary phase is a reverse phase silica
gel and the mobile phase is an organic solvent/water mixture. A C18-derivatized silica gel is an example of a suitable
reverse phase silica gel. Typically, the pH of the mobile
phase is about 1.5 to about 4.0, more preferably about 2.5.
The pH of the mobile phase can be maintained by, for
example, the addition of 0.1 to 2% trifiuoroacetic acid. In a
preferred embodiment, the organic solvent in the mobile
phase is methanol. In another preferred embodiment, the
organic solvent in the mobile phase is ethanol. In another
preferred embodiment, the organic solvent in the mobile
phase is acetonitrile.
In another embodiment, the stationary phase is a normal
phase silica gel and the mobile phase is an organic solvent
mixture. In one embodiment, the organic solvent mixture is
a mixture of an alcohol, a hydrocarbon and an organic base.
Suitable alcohols include, but are not limited to, methanol,
ethanol, n-propanol and isopropanol. Suitable hydrocarbons
include, but are not limited to, heptane, n-heptane, hexane,
isohexane, toluene, cyclohexane, benzene and combinations
thereof. Suitable organic bases include, but are not limited
to, trie th y lamine, die thy lamine, trime ty lamine,
dimethylamine, tripropylamine, tributylamine,
diisopropylethylamine, dicyclohexylamine and diethylisopropylamine. In a preferred embodiment, the organic base is
present in the organic solvent mixture at about 0.05 to about
5%, more preferably at about 0.1 to about 0.5% and, even
more preferably, at about 0.2 to about 0.4%. In a preferred
embodiment, the organic solvent mixture is a mixture of
ethanol, heptane and triethylamine.
In another embodiment, the stationary phase is a chiral
phase silica gel and the mobile phase is an organic solvent
mixture. Suitable chiral phase silica gel stationary phases
include, but are not limited to, CHIRALPAK® ADTM;
CHIRALPAK® ASTM; CHIRALCEL® ODTM; and
CHIRALCEL® OFM, all of which are commercially available from Daicel, through its subsidiary, Chiral Technologies Inc. In one embodiment, the organic solvent mixture is
a mixture of an alcohol (which mayor may not be denatured
with, for example, a hydrocarbon such as n-heptane), a
hydrocarbon and an organic base. Suitable alcohols include,
but are not limited to, methanol, ethanol, n-propanol and

isopropanol. Suitable hydrocarbons include, but are not
limited to, heptane, n-heptane, hexane, isohexane, toluene,
cyclohexane, benzene and combinations thereof. Suitable
organic bases include, but are not limited to, triethylamine,
diethylamine, trimetylamine, dimethylamine,
tripropylamine, tributylamine, diisopropylethylamine, dicyclohexylamine and diethylisopropylamine. In a preferred
embodiment, the organic base is present in the organic
solvent mixture at about 0.05 to about 5%, more preferably
at about 0.1 to about 0.5% and, even more preferably, at
about 0.2 to about 0.4%. In a preferred embodiment, the
organic solvent mixture is a mixture of ethanol, heptane and
triethylamine.
In another embodiment, the compound of Formula V is
further purified using single column chromatography having
a stationary phase and a mobile phase. It has been found that
single column chromatography works surprisingly well for
removing any non-polar impurities found in the reaction
mixture. Suitable stationary and mobile phases are similar to
those described above in connection with the 5MB chromatography.
In another aspect, the present invention provides a method
for preparing a compound of Formula VI having the following structure:
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the method comprising: (a) dissolving a compound of Formula V having the following structure:
40

v
NC

45

50
F

55

60
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in an organic solvent to form a reaction mixture; and (b)
contacting the reaction mixture with HBr to form a product
mixture comprising the compound of Formula VI.
In one embodiment, the organic solvent in step (a) is a
member selected from the group consisting of acetone,
methylethylketone, ethylacetate, toluene, benzene, xylene,
diethylether, t-butylmethylether, dioxane, and mixtures
thereof. In a preferred embodiment, the organic solvent in
step (a) is diethylether. In another preferred embodiment, the
organic solvent in step (a) is acetone.
In one embodiment, the HBr is gaseous HBr. In an
example of this embodiment, the method comprises bubbling gaseous HBr into the reaction mixture to form a
product mixture comprising the compound of Formula VI.
In another embodiment, the HBr is aqueous HBr and the

US 6,967,259 B2
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reaction mixture is contacted with aqueous HBr to form a
primary or secondary amine to form resin-bound demethyland/or didemethyl-impurities, wherein the scavenger resin is
product mixture comprising the compound of Formula VI.
insoluble in the solvent; and (b) filtering the resin-bound
In a preferred embodiment, the above method further
demethyl- and/or didemethyl-impurities, thereby removing
comprises: (c) isolating the compound of Formula VI from
the product mixture. In one embodiment, step (c) comprises: 5 the demethyl and/or didemethyl-impurities from the mixture
of Citalopram.
(i) cooling the product mixture and filtering the product
In one embodiment of the above method, the functional
mixture to obtain the compound of Formula VI as a pregroup on the scavenger resin includes, but is not limited to,
cipitated solid; (ii) washing the precipitated solid with an
isocyanates, isothiocyanates, acid chlorides, esters and
organic solvent; and (iii) drying the precipitated solid to
anhydrides. In some embodiment, the scavenger resin can
obtain the compound of Formula VI. In one embodiment,
step (c) further comprises: (iv) recrystallizing the compound 10 have more than one functional group and, in this case, the
functional groups can be the same or different. It has been
of Formula VI. In one embodiment, the compound of
found that such functional groups react with the primary
Formula VI is recrystallized from a solvent mixture of
and/or secondary amine functionalities present in impurities
toluene and methanol. In another embodiment, the comA and B, virtually in an irreversible fashion, thereby attachpound of Formula VI is recrystallized from a solvent mixture
15 ing impurities A and B to the scavenger resin. The attachof methanol and isopropylalcohol (IPA).
ment of impurities A and B to the scavenger resin renders
In another embodiment, step (iv) comprises: (i') combinsuch impurities insoluble as well.
ing the precipitated solid with toluene and methanol to form
The scavenger resin can be any resin that (1) is insoluble
a mixture and heating the mixture; (ii') filtering the mixture
in the solvent in which the product is dissolved; (2) is
through Celite and slowly cooling the mixture; and (iii')
filtering the mixture to obtain the crystallized solid, washing 20 non-reactive with the solvent in which the product is dissolved; and (3) contains a functional group that is reactive
the crystallized solid with toluene, and drying the crystalwith a primary and/or a secondary amine. In one
lized solid to obtain the compound of Formula VI. In one
embodiment, the scavenger resin is a polystyrene-based
embodiment, in step (ii'), the mixture is cooled to about
resin. In another embodiment, the scavenger resin is a silica
ambient temperature. In another embodiment, in step (ii'),
25 gel-based resin. In a preferred embodiment, the scavenger
the mixture is cooled to about 0° C. to about 5° C.
resin is a polystyrene-based resin having the following
In yet another embodiment, step (iv) comprises: (i')
structure:
combining the precipitated solid with methanol and isopropylalcohol (IPA) to form a mixture and heating the mixture;
(ii') filtering the mixture through Celite and slowly cooling
the mixture; and (iii') filtering the mixture to obtain the 30
crystallized solid, washing the crystallized solid with
isopropylalcohol, and drying the crystallized solid to obtain
the compound of Formula VI. In one embodiment, in step
(ii'), the mixture is cooled to about ambient temperature. In
wherein: R is a functional group that is reactive with a
another embodiment, in step (ii'), the mixture is cooled to
primary and/or secondary amine such as those described
35
about 0° C. to about 5° C.
above.
In another embodiment, the present invention provides a
The above method is typically carried out by stirring a
process for the removal of demethyl-(A) and didemethyl-(B)
crude Citalopram mixture containing A and/or B in an
impurities from crude Citalopram mixtures, wherein the
appropriate solvent with a scavenger resin having a funcdemethyl- and didemethyl-impurities have the following
tional group that is reactive with the primary and/or secstructures:
40 ondary amine functionalities present in A and B, respectively. Suitable solvents include, but are not limited to,
NC
toluene, benzene, xylene, diethylether, t-butylmethylether,
dioxane, and mixtures thereof. The resulting mixture is a
heterogeneous mixture as the scavenger resin is also
45 insoluble in the solvent. It is thought that impurities A and
B, but not Citalopram, attach to the resin by making a
covalent bond between a primary or secondary amine functionality and the functional group on the scavenger resin,
thereby rendering them insoluble. A simple filtration of the
50 resin-bound, i.e., insoluble, impurities A and B affords a
purified Citalopram solution virtually free of impurities A
F
and B.
The above method has a number of significant advantages
including, but not limited to, the following: (1) it selectively
55 renders otherwise soluble impurities A and B insoluble by
binding them to the insoluble resin through the reaction of
the reactive end groups of the scavenger resin and the
Demethyl-(A) and didemethyl-(B) impurities are common
primary and secondary amine functionalities present in
impurities formed at various stages during the preparation of
impurities A and B; (2) the scavenger resin will bind any
Citalopram. Unfortunately, these troublesome impurities
other impurity containing a primary or secondary amine
present a challenge in removal due to their structural prox- 60 functionalities and render them insoluble as well; (3) the
imity to Citalopram.
scavenger resin cannot react with the desired Citalopram,
As such, the present invention provides a method for
which has a tertiary amine functionality; (4) once the resin
binds to the impurities A, B (or any other impurity containremoving demethyl- and didemethyl-impurities from a
ing a primary or secondary amine functionality) rendering
crude Citalopram mixture containing demethyl- and
didemethyl-impurities in a solvent, the method comprising: 65 them insoluble, only a simple filtration is required to remove
these impurities, thereby minimizing any loss (i.e., any loss
(a) contacting the mixture of Citalopram with a scavenger
due to the acid/base wash and/or crystallization and recrysresin having a functional group that is reactive with a

US 6,967,259 B2

13

14

tallization utilized in the method disclosed in PCT Patent
Publication No. WO 01/45483 A2); and (5) once the filtration is performed, a purified Citalopram solution is obtained
and the purified Citalopram can be recovered by a simple
evaporation of the solvent.
The invention will be described in greater detail by way
of specific examples. The following examples are offered for
illustrative purposes, and are not intended to limit the
invention in any manner. Those of skill in the art will readily
recognize a variety of non-critical parameters which can be
changed or modified to yield essentially the same results.

The resulting solution was cooled slowly to 5° C. to
precipitate the product.
The resulting slurry was filtered and washed with
2-butanol (1.60 kg).
The off-white solids were dried at 35-40° C. under
vacuum to yield 1.18 kg (73.8% recovery from crude)
of bromodiol*HCl.
The properties of the Bromodiol*HCl are as follows:
HPLC area % purity: 99.9%.
mp (DSC): 183° C.
lH NMR (d-DMSO): 010.19 (s, lH), 07.0-7.8 (m, 7H),
05.90 (s, lH), 05.17 (s, lH), 04.49 (d, lH), 03.97 (d, lH),
03.02 (m, 2H), 02.65 (s, 6H), 02.21 (m, 2H), 01.65 (m, lH),
01.36 (m, lH).

5

10

EXAMPLES
A. Preparation of Dimetlylaminopropyl Magnesium
Chloride

15

D. Preparation of 5-Bromo-1-(4-fluorophenyl)-1-(3dimethylaminopropyl)-phthalan (,,5-Br")

A 30% aqueous sodium hydroxide (1.04 kg, 7.80 mol,
1.10 eq.) solution was added to a mixture of 65%
A mixture ofbromodiol*HCl (1.12 kg, 2.59 mol, 1.00 eq.)
aqueous dimethylaminopropyl chloride hydrochloride
and 60% phosphoric acid (12.7 kg, 77.8 mol, 30.0 eq.)
(1.71 kg, 7.04 mol, 1.00 eq.) and toluene (0.167 kg) at 20
was heated to 90° C. for 1 h.
<20° C.
The mixture was cooled to <10° C.
The phases were separated.
Toluene (6.72 kg) and water (8.96 kg) were added to the
The organic phase was combined with THF (0.600 kg)
solution and the mixture was quenched with 28%
and dried over molecular sieves (Siliporite NKlO,
aqueous ammonium hydroxide (9.37 kg, 74.9 mol, 28.9
25
0.227 kg).
eq.), maintaining <25° C.
Approximately 5% of the dried dimethylaminopropyl
The phases were separated and the aqueous layer was
chloride solution was added to a mixture of magnesium
re-extracted with toluene (4.48 kg).
(0.170 kg, 7.00 mol, 1.00 eq.), ethyl bromide (0.0038
The organic phases were combined and washed with
kg, 0.035 mol, 0.0050 eq.), and THF (1.60 kg).
water (4.0 kg).
30
The resulting mixture was heated to reflux (>68° C.) and
The solvent was distilled from the washed organic
the remaining dimethylaminopropyl chloride solution
extracts to yield 977 g (99.2% yield, 95.2% yield
was added over 1.5 h.
corrected for residual solvents) of 5-Br as an orange oil.
Reflux (>68° C.) was maintained throughout the addition
The properties of 5-Br are as follows:
period by adjusting the addition rate and heating and/or
HPLC area % purity: 99.0%.
35
cooling as necessary.
lH NMR (d-DMSO): 07.1-7.6 (m, 7H), 05.10 (m, 2H),
The mixture was refluxed (>70° C.) for 1 h, then cooled
02.51 (m, 2H), 02.11 (m, 2H), 02.01 (s, 6H), 01.23 (m, 2H).
to ambient temperature and stored under a dry nitrogen
E. Modified Process for the Preparation of 5-Br
atmosphere.
B. Preparation of (4-Bromo-2-hydroxymethyl)
phenyl-(4-fluoropheny 1)-(3-dimethylaminopropy1)
Methanol Hydrochloride
A solution of 1.1 M 4-fluorophenyl magnesium bromide
in THF (5.57 kg, 6.01 mol, 1.28 eq.) was added to a
mixture of 5-bromophthalide (1.00 kg, 4.69 mol, 1.00
eq), and toluene (6.25 kg) at <20° C. over 1 h.
The mixture was stirred at <20° C. for 0.5 h.
A solution of 1.8 M dimethylaminopropyl magnesium
chloride (3.90 kg, 7.02 mol, 1.50 eq.) was added to the
mixture over 2 h, maintaining <30° C. with cooling.
The resulting mixture was stirred ambient temperature for
16 h.
The mixture was quenched into 6.23% aqueous hydrochloric acid (9.9 kg, 19.3 mol, 4.1 eq.).
The slurry was stirred at ambient temperature for 1 hand
filtered.
The product was then washed with water (2.00 kg) and
toluene (4.00 kg).
The off-white solids were dried at 35-40° C. under
vacuum to yield 1.63 kg (80.4% yield) of crude
bromodiol*HCl.

40
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C. Purification of Bromodiol HCl
A mixture of crude bromodiol*HCl (1.60 kg) and
2-butanol (8.00 kg) was heated to 70° C. to form a hazy
solution and filtered through a bed of celite.

65

A mixture of bromodiol*HCl (0.200 kg, 0.462 mol, 1.00
eq.) and 20% phosphoric acid (2.04 kg, 4.16 mol, 9.00
eq.) was heated to 90° C. for 2.5 h.
The mixture was cooled to <10° C.
Toluene (1.20 kg) was added to the solution and the
mixture was quenched with 28% aqueous ammonium
hydroxide (0.574 kg, 4.59 mol, 9.93 eq.), maintaining
<25° C.
The phases were separated and the aqueous layer was
re-extracted with toluene (0.800 kg).
The organic phases were combined and washed with
water (0.800 kg).
The solvent was distilled from the washed organic
extracts to yield 164 g (93.6% yield) of 5-Br as an
orange oil.
The properties of 5-Br are as follows:
HPLC area % purity: 99.2%.
lH NMR (d-DMSO): 07.1-7.6 (m, 7H), 05.10 (m, 2H),
02.51 (m, 2H), 02.11 (m, 2H), 02.01 (s, 6H), 01.23 (m, 2H).

F. Process for the Preparation of 5-Cyano-1-(3dimethylaminopropyl)-l-(p-fluorophenyl)phthalane
(" Citalopram"or "5-CN")
A solution of 5-bromo-1-(3-dimethylaminopropyl)1-(pfluorophenyl)phthalane (100.5 g, 0.266 mol) in toluene
was added to a mixture of cuprous cyanide (50.0 g,
0.558 mol) and sodium cyanide (9.8 g, 0.200 mol) in of
N,N-dimethylformamide (450 mL)

US 6,967,259 B2
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Toluene was removed by distillation and the resulting
mixture was heated to 154-159° C. under nitrogen until
the desired conversion was achieved.
The reaction mixture was then chilled to 60-70° C. and
quenched with a 10% aqueous NaCN solution (350 g).
Aqueous ethylenediamine (41% solution, 140 g) and
toluene (500 mL) were added and the mixture was
filtered.
The organic layer was separated and the aqueous layer
was extracted with toluene (2x100 mL).
The combined organic extracts were washed with water
(2x100 mL).
The organic extract was then extracted with 20% acetic
acid solution (2x250 mL).
The combined acetic acid extracts were neutralized with
16.6% aqueous NaOH to a pH of about 9 to about 10
and extracted with toluene (3x300 mL).
The combined toluene extracts were treated with activated
charcoal (16.1 g) and stripped of solvent under reduced
pressure to give crude Citalopram (72.3 g, 84%) as a
light brown oil.
The properties of 5-CN are as follows:
HPLC purity: 95% with 5% unreacted 5-Br.
lH NMR (DMSO-d 6 ): 07.6 (s, 1H, 4-H aromatic proton),
6.98 to 7.52 (m, 6H, aromatic protons), 5.25 (d, 1H, 3-HJ,
5.15 (d, lH, 3-H b ), 3.08 (t, 2H, 3'-CH2 ), 2.71 (s, 6H,
-N(CH3)2)' 2.49 to 2.27 (m, 2H, l'-CH 2), 1.82 to 1.71 (m,
2H, 2'-CH 2 );
LC/MS: m/z, 325 (M+1).

16
The properties of Citalopram-HBr are as follows:
mp (DSC): 186° C.
HPLC Purity: 99.8%.
IR(~0:2931,2655,2229,1507,1217,1028,1013,835

5

10

15

cm-\
lH NMR (DMSO-d 6): 09.15 (s, lH, -NH(CH3)2), 7.71
to 7.91 (m, 3H, aromatic protons), 7.52 to 7.64 (m, 2H,
aromatic protons), 7.06 to 7.27 (m, 2H, aromatic protons),
5.08 to 5.28 (q, 2H, 3-H), 3.3 (t, 2H, 3'-CH2 ), 2.65 (s, 6H,
-NH(CH3)2), 2.2 (t, 2H, l'-CH 2), 1.29 to 1.60 (m, 2H,
2'-CH 2 )·
J. Process for the Preparation of 5-Cyano-1-(3dimethylaminopropyl)-l-(p-fiuorophenyl)phthalane
HBr (Citalopram-HBr)
In addition to the foregoing method, Citalopram.HBr can
be prepared using aqueous HBr. It has been found that the
resulting product prepared using aqueous HBr is equivalent
to that prepared using gaseous HBr in both yield and purity.

20

C.HBr Salt Formation

25

48% HBr (aq) (54.1 g, 0.321 mol) is added to a stirred
solution of 5-CN (104.1 g, 0.31 mol) in Toluene (366
g) at 5-10° C.
The resulting slurry is cooled to 0-5° C. and filtered.
The product is washed with cold Toluene (2x107 mL) and
dried in vacuo (60-80° C. at 5-10 mm Hg) to afford
C-HBr (97.5 g, 93.6%) as a white solid.

30

Recrystallization/Purification
G. Process for the Purification of Crude 5-CN
The crude 5-CN product is dissolved in a mixture of
heptane/ethanoIITEA(90%:1O%:0.1 %), and separated using
Multi-Column Chromatography (MCC) equipment (SMB)
to provide 5-CN with <0.1% 5-Br. The mobile phase is
heptane/ethanoIITFA. The stationary phase is CHIRALCEL
ODTM. MCC separation has been demonstrated on 400 g
scale and the product isolated from the separation was
>99.9% pure. The product was so pure that when it was
converted to the HBr salt, it maintained its purity and did not
require additional purification-a 20% savings in the yield.
H. Process for the Preparation of 5-Cyano-1-(3dimethlylaminopropyl)-l-(p-fiuorophenyl)phthalane
HBr (Citalopram-HBr)
HBr gas (18.0 g, 0.223 mol) was bubbled into a stirred
solution of pure 5-CN (72.3 g, 0.223 mol) in 723 mL
acetone at 20-25° C.
The resulting slurry was cooled to 0-5° C. and filtered.
The product was washed with cold acetone (3x100 mL)
and dried in vacuo (60-80° C. at 5-10 mmHg) to give
Citalopram-HBr (69.8 g, 77.3%), a white solid.

35
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mp (ose):
HPLC Purity:
50 5-Br:
Total Impurities:
Unknown Inpurities
IR(KBr):

55

I. Purification of Citalopram-HBr

A mixture of the crude product (69.8 g), toluene (1117 g),
and methanol (138 g) was heated to 60-70° C.
The resulting solution was filtered through celite and
slowly cooled to ambient temperature.
The crystallized solid was filtered, washed with 100 mL
toluene, and dried in vacuo (60-80° C. at 10 mmHg) to
give pure Citalopram-HBr (53.2 g, 76.2%), a white
solid.

A recrystallization is not necessary when using 5-CN
purified by 5MB chromatography. However, the following
can be performed if further purification is required or
desired.
A mixture of C-HBr (97.5 g, 0.301 mol), methanol (103.6
g) and isopropanol (207.2 g) is heated to 60-70° C.
The resulting solution was cooled to 0° C. and filtered.
The recrystallized product was washed with cold isopropanol (2x75 mL) and dried in vacuo (60-80° C. at 5-10
mm Hg) to afford C-HBr (88.6 g, 85.1%) as a white
solid.
The properties/characterization of pure C-HBr are as
follows:

187 0 C.
99.8%
None detected
~0.2%
~0.1 %:

'H NMR (OMSO-do):

None detected
2931, 2655, 2229, 1507, 1217, 1028,
1013, 835 cm-';
09.15 (s, lH, -NH(CH3 hl, 7.71 to 7.91
(m, 3H, aromatic protons), 7.52 to 7.64
(m, 2H, aromatic protons), 7.06 to 7.27
(m, 2H, aromatic protons), 5.08 to 5.28
(q, 2H, 3-H), 3.3 (t, 2H, 3'-CH2),
2.65 (s, 6H, -NH(CI:h)2), 2.2 (t, 2H,
l'-CH2), 1.29 to 1.60 (m, 2H, 2'-CH2).

60

K. Removal of Demethyl and Didemethyl
Impurites from a Crude Citalopram Mixture
65

Methylisocyanate polystyrene resin (0.34 g, 0.18 mol
isocyanate) is added to a solution of 5-CN (0.92 g) in
Toluene (10 g) and stirred at room temperature.
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After 2 h at room temperature, the resin was filtered and
Toluene was evaporated in vacuo (50-60° C. at 5-10
mm Hg) to afford product with 70% less demethyl
impurity (A).

Product Recovery

Each recovered fraction (extract and raffinate) was evaporated in 20-L rotary evaporators (Genser, Germany). The
5 Extract fraction was evaporated to dryness and the product
L. 5MB Purification of Citalopram-HBr
was recovered as a crystal. The evaporation step was conExperimental
ducted at 40-° C. (waster bath) and under vacuum (150-mbar
The feed mixture is an oil recovered from the cyanation
to start the process and down to 80-mbar for drying the
step and contains several impurities (polar and non-polar).
product) with 50-rpm for the flask speed.
These impurities can mostly be removed by standard 10
The solvent recovered was sampled and tested and acceptreworking of the product (e.g., by crystallization and solvent
able low amount of product was detected (traces).
exchange). However, one impurity is not removed by these
techniques. This impurity is the starting material of the
The raffinate was re-dissolved in a small amount of
previous step. It is the 5-Br intermediate that is converted
ethanol
denatured and evaporated in a 1-L flask using the
into Citalopram during the cyanation step.
15
laboratory evaporator (Buchii). The raffinate product (5-Br)
The separation of a mixture of Citalopram and 5-Br
was recovered as a viscous oil.
intermediate in the proportion 95/5 (HPLC area % at 232nm) was examined by chromatography and more specifiA sample of each recovered fraction was analyzed using
cally by the simulated moving bed technique. FIG. 3 20
a C 18 column (reverse phase) and a gradient of water with
(reverse phase analysis) gives an example of the feed
TFA (trifluoroaceticacid) and acetonitrile with TFA.
composition. The largest peak is the Citalopram peak. The
second largest peak is the 5-Br intermediate. The other peaks
Separation Performance
are of lesser interest for the chromatographic separation.
The following equipment was used for the experiment. 25
The total quantity of product recovered is 675.3-g (all
5MB unit: Licosep laboratory unit from NOVASEP
fractions included), which gives an overall yield for the
(Brabois (54), France) equipped with 8 axial compression
process of 96%. The 4% loss is due to product loss in the
columns from MERCK (Darmstadt, Germany). Each colequipment (tanks walls, tubing, 5MB unit) and when recovumn was 50-mm internal diameter and was prepared using
ering the fractions.
110-g of CHIRALCEL ODTM 20-,um chiral stationary phase 30
(Chiral Technologies Inc, Exton, USA). The average column
The expected quantity of 5-CN to be recovered was
length was 1O.3-cm. The mobile phase used for the separa641.5-g. The total extract collected was 576.2-g representing
tion was a mixture of ethanol (denatured with n-heptane)
a recovery yield of 89.8%.
and n-heptane in the proportion 10/90% (v/v.). Triethylamine was added as a modifier (0.2% total volume). The 35
The product obtained in the extract does not contain
separation was conducted at 30° C. Under such conditions,
detectable amount of 5-Br (see, FIGS. 4 and 5).
the compound of interest (Citalopram) is the second eluting
compound and will be designed as the Extract, 5-Br will be
Based on these experimental data, the production rate for
the Raffinate.
the separation is 1.31-kg/d of 5-CN at 17 bars. This correEach column was individually tested with a diluted solu- 40 sponds to a productivity of 1.49 kg of Citalopram per day per
tion of the mixture to be separated (14.2-gll). The injected
kg of CSP at 17 bars (free of 5-Br).
volume was O.5-ml. Detection was performed at 254-nm and
the flow rate was 100-mllmin. The 5-Br average elution time
[Let's discuss whether or not to include the loading study
is 1.92-min while the Citalopram has an averaged elution
as well as the other information in the discussion section]
time of 3.1O-min. The average to (or dead volume) of the
45
column was 1.51-min. The average retention factor for the
It is understood that the examples and embodiments
5-Br was 0.27 and was 1.04 for the Citalopram. The average
described herein are for illustrative purposes only and that
selectivity of the separation was 3.84.
various modifications or changes in light thereof will be
Separation Parameters
suggested to persons skilled in the art and are to be included
The separation was conducted using 703.1 g of a mixture 50 within the spirit and purview of this application and scope of
of Citalopram and 5-Br prepared according to the cyanation
the appended claims. All publications, patents, and patent
procedure. The feed composition is 95% of Citalopram and
applications cited herein are hereby incorporated by refer5% of 5-Br (area % by HPLC at 232-nm). The feed contains
ence for all purposes.
other impurities, but they were not taken into account in the
What is claimed is:
calculation of the feed composition. The feed concentration 55
for this step was 22.7-gll.
1. A method for preparing a salt of the compound of
The set of parameters used for the separation was:
Formula III having the following structure:

Period
min

Eluent
ml/min

Zone I
(recycle)
ml/min

Extract
ml/min

Zone II
ml/min

1.65

86.7

190

76.7

113.3

Feed Zone III
ml/min ml/min
40@
22.7 gil

153.3

Raffinate
ml/min

Zone IV
ml/min

50

103.3
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(b)contacting said intermediate of Formula II with dimethylaminopropyl magnesium chloride in an organic
III
OH
solvent to form a reaction mixture; and
(c) quenching said reaction mixture with an acid to form
a product mixture comprising said salt of the compound
5
of Formula III.
2. The method of claim 1, wherein said salt of the
compound of Formula II is an acid salt.
3. The method of claim 2, wherein said acid salt is a
member selected from the group consisting of a HCI salt, a
10 HEr salt, a H 2 S0 4 salt, a H 3 P0 4 salt, a methanesulfonic acid
salt, a trifiuoroacetic acid salt, an acetic acid salt, a fumaric
acid salt and a citric acid salt.
4. The method of claim 1, wherein said organic solvent in
F
step (b) is a member selected from the group consisting of
15 diethylether, t-butylmethylether, THF, dioxane, toluene,
xylene and mixtures thereof.
said method comprising:
5. The method of claim 1, wherein said organic solvent in
(a) contacting a compound of Formula I having the
step (b) is a mixture of THF and toluene.
following structure:
6. The method of claim 1, wherein said acid in step (c) is
20 a member selected from the group consisting of HCI, HEr,
H 2 S0 4 , H3 P0 4 , methanesulfonic acid, trifiuoroacetic acid,
acetic acid, fuinaric acid and citric acid.
7. The method of claim 1, wherein said acid is aqueous
0
HCI.
#
8. The method of claim 1 further comprising:
25
o
(d) isolating said salt of the compound of Formula III
from said product mixture.
9. The method of claim 8, wherein step (d) comprises:
with 4-fiuorophenyl magnesium bromide to form an inter(i) filtering said product mixture to obtain said salt of the
mediate of Formula II having the following structure:
compound of Formula III.
30
10. The method of claim 9, wherein step (d) further
II
comprises:
(ii) washing said salt of the compound of Fonnula III with
water and toluene.
35
11. The method of claim 10, wherein step (d) further
comprises:
(iii) recrystallizing said salt of the compound of Formula
III from a member selected from the group consisting
of I-butanol, 2-butanol and water.
40
12. The method of claim 11, wherein step (d) further
comprises:
(iv) recrystallizing said salt of the compound of Formula
III from 2-butanoI.
F

Br

BrD=<
I

Br
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